Oncolytic Molecules that Kill Cancer with Direct & Abscopal Tumor Effects

Lytix Biopharma is Redefining the Standard of Care in the Neoadjuvant Setting

Lytix Biopharma is developing a pipeline of oncolytic molecule therapies that treat both superficial and deep-seated tumors. Our focus is to re-define the standard of care in the neoadjuvant (pre-surgery) setting, through providing patients with first-in-class, first-line immunotherapies that kill cancer with direct and abscopal tumor effects.

Our mission is to deliver transformative medicines that work in synergy with immune checkpoint inhibitors, to offer patients the best outcomes in the pre-surgical setting with a full immune system intact.